Mycosis fungoides and Sézary syndrome: The burden of pruritus

Community Oncology

Volumn 7, Issue 9, 2010, Pages 399-404

  Demierre, Marie France ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BEXAROTENE; DENILEUKIN DIFTITOX; GABAPENTIN; ISTODAX; MIRTAZAPINE; PROTEINASE ACTIVATED RECEPTOR 2; ROMIDEPSIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VORINOSTAT; ZANOLIMUMAB;

ADVANCED CANCER; ANTIGEN PRESENTATION; CUTANEOUS T CELL LYMPHOMA; DAILY LIFE ACTIVITY; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNE RESPONSE; MYCOSIS FUNGOIDES; PATHOPHYSIOLOGY; PRURITUS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SEZARY SYNDROME; SLEEP DISORDER; TH1 CELL; TH2 CELL; VISUAL ANALOG SCALE;

EID: 78549247457     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70414-4     Document Type: Review

References (32)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
2. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-859.
3. . Cutaneous Lymphoma Foundation. CTCL- MF Fast Facts. http://www.clfoundation. org/about_cutaneous_lymphoma/CL_ fast_facts.htm. Accessed August 11, 2010.
4. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-1988.
5. Dummer R, Hess-Schmid M, Burg G. Cutaneous T-cell lymphomas: prognosis and quality-of-life issues. Clin Lymphoma 2000;1(suppl 1):S21-S25.
6. Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009;160:815-822.
7. Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006;107:2504-2511.
8. Demierre MF, Tien A, Miller D. Healthrelated quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 2005;141:325-330.
9. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1485-1507.
10. Demierre MF, Ferzli P, Miller D. Measuring HRQOL in patients with cutaneous Tcell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Arch Dermatol 2007;143:659-661.
11. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008;59:234-244.
12. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-4272.
13. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115.
14. Lerner A, Demierre MF, Whittaker S, et al. Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatmentrefractory CTCL: interim report of a phase II multicenter study. Blood 2006;108:2468.
15. Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. QJM 2003;96:7-26.
16. Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007;87:291-294.
17. Peters EM, Ericson ME, Hosoi J, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006;126:1937-1947.
18. Reddy VB, Iuga AO, Shimada SG, La- Motte RH, Lerner EA. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 2008;28:4331-4335.
19. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176-6180.
20. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008;159:105-112.
21. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 1997;89:32-40.
22. Yosipovitch G. The pruritus receptor unit: a target for novel therapies. J Invest Dermatol 2007;127:1857-1859.
23. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994;103:669-673.
24. . The Leukemia & Lymphoma Society. Cutaneous T-cell lymphoma. http://www.leukemia- lymphoma.org/attachments/National/ br_1163608564.pdf. 2006. Accessed August 11, 2010.
25. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006;55:543-544.
26. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
27. Kim HY, Reddy S, Kim EJ, et al. Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: an international multicenter study. Blood 2007;110:123.
28. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
29. Duvic M, Kuzel TM, Olsen EA, et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2002;2:222-228.
30. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous Tcell lymphoma. Blood 2007;109:4655-4662.
31. Whittaker S, Scarisbrick J, Kim Y, et al. Romidepsin has activity in refractory CTCL: an international multicenter study [abstract]. J Invest Dermatol 2008;128(suppl):S74.
32. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008;59:234-244.